Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CV-18C3 · 1 trial · 1 indication
adverse events, vitals signs, physical examination results and clinical laboratory values
| Arm | Type | Description |
|---|---|---|
| CV-18C3 and standard of care | EXPERIMENTAL | CV-18C3 and standard of care |
| standard of care | ACTIVE_COMPARATOR | Percutaneous revascularization |
| Name | Type | Description |
|---|---|---|
| CV-18C3 | DRUG | 3.75mg/kg given IV for a period of 6 weeks, followed by subcutaneous administration |
| Standard of Care | PROCEDURE | - |
Inclusion Criteria: * Have suspected superficial femoro-popliteal artery occlusion due to lower extremity pain with exercise or at rest and are undergoing a planned arteriogram. * Subjects will be randomized after angiographic evidence of qualifying lesion Exclusion Criteria: * Acute critical lim...
CV-18C3 is an investigational small molecule being studied for use in patients undergoing repeat peripheral artery revascularization. It is being developed for the cardiovascular therapeutic area. The drug is currently in Phase 2 clinical development and is not approved by the FDA.
CV-18C3 is being developed by Johnson & Johnson, a company listed on the stock exchange under the ticker JNJ. The drug is currently in Phase 2 clinical development for patients undergoing repeat peripheral artery revascularization.
CV-18C3 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. A Phase 2 clinical trial for the drug has been completed, and it is being studied in patients undergoing repeat peripheral artery revascularization.
CV-18C3 has one completed clinical trial, identified as NCT01270945. This Phase 2 study, titled "Safety and Preliminary Efficacy Study of an Anti-inflammatory Therapeutic Antibody in Reducing Restenosis," enrolled 43 participants in the United States. The trial was active-controlled and included patients undergoing repeat peripheral artery revascularization.
CV-18C3 is the drug being studied in a clinical trial titled "Safety and Preliminary Efficacy Study of an Anti-inflammatory Therapeutic Antibody in Reducing Restenosis." The trial description refers to the investigational drug as an anti-inflammatory therapeutic antibody, and CV-18C3 is the drug evaluated in that study.